Table 1.

Clinical and molecular characteristics of lung adenocarcinoma patients.

	Diagnosis age groups (No.)
Characteristics	≤40	41-45	46-50	51-55	56-60	61-65	66-70	71-75	76-80	>80	Total	P value
Patients	18	24	43	64	117	125	136	115	80	51	773	/
Sex
Male	5	10	8	15	45	60	64	55	44	25	331	<.001
Female	13	14	35	49	72	65	72	60	36	26	442
Smoking status
Never	9	7	13	19	30	27	32	19	17	15	188	.043
Former/current	9	17	30	45	85	98	102	92	62	35	575†
Stage
I-IIIA	0	6	8	19	38	42	57	43	22	22	257	.005
IIIB-IV	18	18	35	45	78	83	77	71	57	29	511‡
Targetable genotype
Positive	13	12	16	28	40	51	41	39	16	16	272	<.001
Negative	5	12	27	36	77	74	95	76	64	35	501
EGFR
Mutant	7	6	9	12	22	28	22	20	6	8	140	.008
Nonmutant	11	18	34	52	95	97	114	95	74	43	633
ALK
Mutant	2	2	2	3	5	3	3	3	2	0	25	.017
Nonmutant	16	22	41	61	112	122	133	112	78	51	748
ROS1
Mutant	2	0	1	4	1	4	0	3	1	0	16	.055
Nonmutant	16	24	42	60	116	121	136	112	79	51	757
RET
Mutant	2	2	0	3	3	1	1	0	0	0	12	<.001
Nonmutant	16	22	43	61	114	124	135	112	80	51	758
BRAF-V600E
Mutant	0	1	0	1	2	3	5	1	2	1	16	.686
Nonmutant	18	23	43	63	115	122	131	114	78	50	757
MET
Mutant	0	1	2	3	4	8	4	8	5	6	41	.067
Nonmutant	18	23	41	61	113	117	132	107	75	45	732
ERBB2
Mutant	0	0	2	2	3	4	6	4	0	1	22	.720
Nonmutant	18	24	41	62	114	121	130	111	80	50	751
KRAS
Mutant	1	1	10	23	34	31	46	33	39	20	238	<.001
Nonmutant	17	23	33	41	83	94	90	82	41	31	535

Note: ^†10 patients with unknown smoking history were excluded from analysis. ^‡5 patients with unknown stage at diagnosis were excluded from analysis. P < .05 was used to define statistical significance.